Physician profile
Ehsan Rafiq
NPI 1801029608
$3,610.60
in general payments reported to CMS, 2019-2025
29 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $212 · 2021: $247 · 2022: $750 · 2023: $575 · 2024: $684 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,332.42 | 2019-2025 | |
| Genzyme Corporation | $312.62 | 2022-2025 | |
| Janssen Biotech, INC. | $261.28 | 2021-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $256.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Pharmaceuticals, INC. | $133.20 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $114.60 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $110.06 | 2022 | |
| Pentax of America, INC. | $108.85 | 2022 | |
| Angiodynamics, INC. | $103.12 | 2019 | |
| Covidien LP | $87.82 | 2019 | |
| Celgene Corporation | $81.70 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.66 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $73.58 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $73.47 | 2021-2023 | Suflave |
| Regeneron Healthcare Solutions, INC. | $55.92 | 2024 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $54.49 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $52.44 | 2024-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $47.84 | 2024 | Voquezna |
| Ambu INC. | $43.82 | 2021 | |
| Pfizer INC. | $39.66 | 2020-2021 | |
| Qol Medical, LLC | $31.24 | 2024 | Sucraid |
| Novo Nordisk INC | $28.69 | 2025 | Wegovy |
| Olympus America INC. | $28.37 | 2023-2024 | Evis Exera III Colonovideoscope |
| Aimmune Therapeutics, INC. | $23.63 | 2025 | Zenpep |
| Celltrion USA INC. | $18.95 | 2025 | Vegzelma |
| Boston Scientific Corporation | $18.44 | 2020 | |
| Medtronic, INC. | $16.67 | 2025 | Gi Genius |
| Redhill Biopharma INC. | $14.81 | 2021 | |
| Grifols USA, LLC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehsan Rafiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.